27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Evidence suggests that delirium is associated with long-term poor outcome but delirium often occurs in individuals with more severe underlying disease. 5 key findings →
Design: meta-analysis Participants: 714 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Individual statins were not significantly associated with risk of Parkinson's disease, rheumatoid arthritis, venous thromboembolism, dementia, osteoporotic fracture, gastric cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer. 3 key findings →
Design: cohort study Participants: 692 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
ADNI has demonstrated the feasibility and utility of multicenter PET studies and is helping to clarify the role of biomarkers in the study of aging and dementia. 3 key findings →
Design: longitudinal study Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The prediction of dementia in AD by SMI with subsequent amnestic MCI supports the model of a consecutive 3-stage clinical manifestation of AD from SMI via MCI to dementia. 2 key findings →
Design: cohort study Participants: 2,415 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
MCI is common in patients with PD without dementia, affecting a range of cognitive domains, including memory, visual-spatial, and attention/executive abilities. 2 key findings →
Participants: 1,346 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The mean baseline age of the veterans was 68.8 years, and 174 806 (96.5%) were men. 4 key findings →
Design: cohort study Participants: 181 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer's disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population. 5 key findings →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Severe psoriasis is associated with an increased risk of death from a variety of causes, with cardiovascular death being the most common aetiology. 4 key findings →
Design: cohort study Participants: 3,603 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Using exome sequencing, we identified a p.R191Q amino acid change in the valosin-containing protein (VCP) gene in an Italian family with autosomal dominantly inherited amyotrophic lateral sclerosis (ALS). 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In a large community-based sample of middle-aged adults, BI predicted an increased risk of stroke and dementia independent of vascular risk factors. 5 key findings →
Participants: 1,694 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These data demonstrate that YKL-40, a putative indicator of neuroinflammation, is elevated in AD and, together with Aβ42, has potential prognostic utility as a biomarker for preclinical AD. 3 key findings →
Participants: 47 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dramatic increases in the numbers of "oldest old" (aged 85 years and older) across all racial and ethnic groups will also significantly affect the numbers of people living with AD. 1 key finding →
Participants: 200,000 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia, depression and anxiety disorders are the most common psychiatric disorders among older adults in LTC. 3 key findings →
Participants: 74 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study of patients with semantic dementia, a variant of frontotemporal lobar degeneration, has emerged over the last two decades as an important lesion model for studying human semantic memory. 4 key findings →
Participants: 21 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Frailty is a risk for postoperative complications and an independent predictor of in-hospital mortality, institutional discharge, and reduced midterm survival. 1 key finding →
Participants: 3,826 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Clinical and epidemiologic research has focused on the identification of risk factors that may be modified in predementia syndromes, at a preclinical and early clinical stage of dementing disorders, with specific attention to the role of depression. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patients had undetectable HIV-1 RNA concentrations for a median time of 48 months (range 3.2-136.6). 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of dementia is increasing with expansion of the older adult population. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
During the past century, treatments for the diseases of youth and middle age have helped raise life expectancy significantly. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →